Early Experience of Treprostinil Dry-Powdered Inhaler in Patients With Pulmonary Hypertension Related to Fibrosing Interstitial Lung Disease at a Tertiary Referral Center

In this first global study of patient perspectives in Group 2 and 3 PH, we demonstrate that those with Group 3 PH report significantly greater adverse impacts on physical and mental wellbeing than those in Group 2 or Group 1, despite a lower treatment side-effect profile.

In this PH Community Call, we discussed: 

• Subcutaneous Treprostinil in PH Associated With Left Heart Disease or Chronic Lung Disease
• Ferroportin Inhibition Attenuates Pulmonary Hypertension in Hypoxic Sickle Cell Disease Mice 
• Artificial Intelligence-Based Echocardiography in Pulmonary Arterial Hypertension 

Presented at PVRI 2026 Congress by Vasile Foris, Medical University of Graz

Presented at PVRI 2026 Congress by Silvia Ulrich, University of Zurich